Business
iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025
NASHVILLE, Tenn., July 28, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, August 15, 2025 at 4:00 PM ET featuring Anthony Langone, MD (Associate Professor of Medicine, Division of Nephrology and Hypertension, Vanderbilt University). To register, click here. Dr. Langone, who serves as the national principal investigator (NPI) for iMDx’s ongoing kidney transplant monitoring trial
About this update from Insight Molecular Diagnostics Inc.
[{"type":"image","alt":"Insight Molecular Diagnostics Inc.","displaySize":"","headline":null,"caption":"Insight Molecular Diagnostics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a9omE9cBUejfoy9a_jJadQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4","width":300,"height":114}},"lazy":false},{"type":"text","content":"NASHVILLE, Tenn., July 28, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, August 15, 2025 at 4:00 PM ET featuring Anthony Langone, MD (Associate Professor of Medicine, Division of Nephrology and Hypertension, Vanderbilt University). To register, click here.","length":377,"tagName":"p"},{"type":"text","content":"Dr. Langone, who serves as the national principal investigator (NPI) for iMDx’s ongoing kidney transplant monitoring trial, will discuss the expanding role of donor-derived cell-free DNA (dd-cfDNA) in transplant care, patient management, and the benefits of enabling in-house testing.","length":284,"tagName":"p"},{"type":"text","content":"In addition, the Company's management team will provide an overview of their kitted strategy, and the uniqueness of their GraftAssure™-branded in-house testing option. The GraftAssure™ family of assays, already available in lab-developed test form and as research-use-only kits, leverages advanced digital PCR (dPCR) technology to deliver highly quantitative, reliable dd-cfDNA results for transplant monitoring. The Company is developing a diagnostics test kit for clinical use, to enable hospitals to run their own tests, in-house.","length":537,"tagName":"p"},{"type":"text","content":"A live question and answer session will follow the formal presentations. Those who are registered but unable to attend the virtual event live may send questions in advance of the event to [email protected]. Please send your questions at least 12 hours in advance of the event.","length":288,"tagName":"p"},{"type":"text","content":"About Anthony Langone, MD","length":25,"tagName":"p"},{"type":"text","content":"Anthony Langone, MD ...